Member Info for Soupdragon78

Annes day to day actions don't bother me, we all know the strategy, its been in place since she joined.

If NXP002 inhaled comes good then surely must be worth it as I doubt the company could achieve it without her.

That sounds like she's got more acumen than someone spending their time posting on an anonymous bulletin board for free all day.

Two things can happen,

1 - the company finalise the Oxilio deal, personally I'm not bothered about whether its 'good' or not, I just want a result.
2 - The broker should be developing interest from prospective investors and getting them onboard with a view to someone buying enough for a TR1. (Some well known ex-forum poster said on twitter after the placing that a 'well-known' name was accumulating, but that has shown to be bs like when they said the deal was done and ready last July.)

Moreover, are Allenby being proactive in pushing their large clients to invest? They should be all over this right now given they've said current value should be 1.7-3.4p.

Filter, what can they do? 002 and 004 are awaiting results that can't be magicked out of thin air. The only thing they've got is the Ox deal to push forward.

This is the problem when they shifted away from operating a service for the likes of Ebers, Vistagen etc, they are not chasing any business, just sat around waiting for data. There is literally nothing for them to do on a day to day basis.

Its the Friday sellers club.

Answers will be on the 24th or after.

"We will endeavour to respond to all questions received by 10.00am on 18 August 2021 with the Q&A that will be published on the Company website soon after the AGM"

Has anybody tried such a thing as a dump and pump?

Although it sounds like something a tory minister would be into.

Understandable, but I’m just at the point that I want something to be sorted and give some positivity back to the company, it’s the only thing we will see in the near term as others are all now Q4, having slipped back from Q3.

awww. bless them for finding the copy paste buttons.

Just bored really, trying to see if I can find anything that might give some sort of clue. Particularly as Riddell said news on 002 and 004 would be in Q4, so that'll be quiet for a while yet.

One caveat is that Biocopea are described as 'biology based', quite whether that fits in with NXP001 I'm not sure.

"Biocopea is a biology based product discovery company with a proprietary and proven pharmacodynamic drug enhancement and delivery technology, Lipicore. Lipicore technology has been proven at scale and the first product using the technology has been launched and commercialised as the best-in-class repurposed NSAID, Flarin. Following this success, Biocopea is now focussed on maximising the value from this technology through development of its own pipeline of repurposed best in class drugs and through collaboration."

Agreed, if still no news on Ox then it will be dissapointing.

On that, I've been trying to figure out the link between Oxilio and Biocopea Ltd. The Ox website shows they signed an MOU and Heads of Terms in January with them.

Biocopea is run by Robin Bannister, who coincidentally founded Arakis with Julian Gilbert of NFX.

They are 71% owned by Peptcell (https://www.seekacure.com/) who have a decent track record of developing products and then spinning them out (including Flarin Lipicore, a kind of ibuprofen)

Thinking that even if Oxilio sign up to licence NXP001 they still need someone to do the clinical work. This is something that Biocopea seem to be able to do.

Well thats one out of the way with no knock on the price, 313,020.

Just need news to come our way.

Traders try to find their way out today. Pretty much all at a loss.

Good to see it hang on despite yesterdays 500k seller being desperate to exit. Its good when the MM's won't take their shares.

Everyone else who bought yesterdays rise will now face the fact they need to hold on as they can't sell at a profit. Only 8 trades from yesterday were below the current sell price, and they've all been sold.

Traders being made to sweat.

As picked up by VelarDB on twitter.

US2021155577A1 CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE
F: IP right grant
INFORMATION ON STATUS: PATENT GRANT
2021-07-14

https://worldwide.espacenet.com/patent/search/family/067997566/publication/US2021155577A1?q=nuformix

Chab, only those that are highlighted in the Allenby report developing inhaled IPF treatment and are currently in Phase II and III.

The logical question would be...if a deal is on, why would Brindley resign? As she would leave on a deal anyway.

Resigning implies that she saw the role being the same in the future. Or she wanted to leave immediately but Riddell has forced her to see out her contract.

This mornings 500k buyer is trying to exit for a couple of hundred quid now.